Astro-Med, Inc. Reports Fourth Quarter and Fiscal 2010 Results; Directors Increase Quarterly Cash Dividend


WEST WARWICK, RI, Mar 16, 2010 (MARKETWIRE via COMTEX) -- Astro-Med, Inc. (NASDAQ: ALOT) reports Net Income of $1,728,000, equal to $0.23 per diluted share on sales of $16,281,000 for the Fourth Quarter ended January 31, 2010. During the comparable period of the previous year, the Company reported net income of $263,000, equal to $0.04 per diluted share on sales of $15,631,000.

New Orders; Net Sales

During the Fourth Quarter, Astro-Med, Inc. received $17,538,000 in orders, up 15 percent over the comparable quarter of the prior year. Sales revenues were also higher by 4.2% over the previous year's Fourth Quarter. The Company reports that the growth was driven by its consumables product lines, which posted a Year-Over-Year quarterly increase of 17.8%.

Gross profits were up approximately 4% and produced a margin on sales of 41.8%. Operating income was higher by 83% from last year and generated a margin of approximately 4%, excluding a one time gain related to successful litigation.

During the twelve month period of the Fiscal Year, Net Income was $2,766,000, equal to $0.38 per diluted share, on sales of $64,031,000. For the comparable period last year, the Company reported Net Income of $2,964,000, equal to $0.40 per diluted share, on sales of $71,783,000. If non-recurring items were excluded from the Fourth Quarter, Net Income for the year would have totaled $1,415,000, equal to $0.19 per diluted share.

Strong Fundamentals

Management reports that it strengthened Astro-Med, Inc.'s financial position during Fiscal Year 2010 by increasing its cash and investment position to $23,760,000; improving its current ratio to 6.12:1, raising the efficiency of the turnover in the Company's accounts receivable and inventory assets; enhancing the book value of the Company's equity position to $7.52 per share at Year End, and successfully litigating the integrity of the Company's employment contracts against a direct competitor.

Impact of Foreign Currency, Taxes, and Litigation

Favorable foreign currency exchange rates added approximately $395,000, or 2.4%, to Fourth Quarter sales. Net Income in the Fourth Quarter includes $335,000, equal to $0.04 per diluted share, for a tax benefit pertaining to previously uncertain tax provisions. In addition to the income tax benefit, Net Income in the Fourth Quarter includes a gain of $112,000, equal to $0.02 per diluted share, related to the acquisition we made on December 15, 2009 and $904,000 net of tax from the successful outcome of litigation, equal to $0.12 per diluted share.

Unfavorable foreign currency exchange rates reduced Fiscal 2010 annual sales by approximately $744,000, or 1.2%.

Cost Savings; Expansion; New Products

Commenting on the results, Albert W. Ondis, Chief Executive Officer, stated: "I am pleased with the good progress we have made in implementing the first leg of the Company's Three Year (FY2011-FY 2013) Strategic Plan, notwithstanding the current unsettled global economic environment. I count among our accomplishments the following activities:

We have achieved these initiatives without compromising Astro-Med, Inc.'s Sales and Marketing organization or our Research and Development organization, which allowed us to preserve these key drivers of our growth for the year to come. I am looking forward to the exciting products and strategies which will unfold as Fiscal 2011 gets underway."

Financial Guidance

The Company expects that for FY 2011, revenue will be in the range of $71 - $73 million and earnings per diluted share will be in the range of $0.35 to $0.40.

Directors Declare Increase in Quarterly Dividend

In a regular meeting of the Astro-Med, Inc. Board of Directors, on March 15, 2010, the Directors voted to increase the quarterly dividend by $.01 per share to $0.07. The dividend is payable on April 2, 2010 to shareholders of record on March 19, 2010. The Board's decision came after it approved Management's progress toward the Company's Three Year Strategic Business plan and the Budget for Fiscal 2011.

Commenting on the results, Albert W. Ondis, Chairman and CEO, said, "It pleases me greatly to be able to return more of our earnings to our shareholders. It is gratifying that our cash and investments position and our earnings allow us to pay shareholders increased dividends."

Conference Call on Wednesday, March 17, 2010 at 11:00 am Eastern Time

The Fourth Quarter conference call will be held on Wednesday, March 17, 2010 at 11:00 AM EDT. It will be broadcast in real time on the Internet through the Investing section of our website. We invite you to log on and listen in real time on March 17th, or to participate in the conference call by dialing 877-941-9205 with password 4219982. Following the live broadcast, an audio webcast of the call will be available for ten days at A conference call replay will also be available for ten days by dialing 800-406-7325 with password 4219982.

About Astro-Med, Inc.

Astro-Med, Inc. is a leading manufacturer of specialty high tech printing systems, electronic medical instrumentation, and test and measurement instruments. Astro-Med, Inc. products are sold under the brand names Astro-Med(R), Grass(R) Technologies and QuickLabel(R) Systems and are employed around the world in a wide range of aerospace, medical, military, industrial, and packaging applications. Astro-Med, Inc. is a member of the Russell Microcap(R) Index. Additional information is available by visiting

                                 ASTRO-MED, INC.
                    Consolidated Statements of Operations
                    In Thousands Except for Per Share Data
                              Three-Months Ended      Twelve-Months Ended
                              January     January     January     January
                             31, 2010    31, 2009    31, 2010    31, 2009
                            ----------  ----------  ----------  ----------
Net Sales                   $   16,281  $   15,631  $   64,031  $   71,783
Gross Profit                     6,805       6,553  $   26,628  $   31,068
                                  41.8%       41.9%       41.6%       43.3%
Operating Expenses:
   Selling                       3,895       4,014      15,342      16,942
   General & Administration      1,080       1,020       4,503       4,615
   Research & Development        1,254       1,205       4,820       4,885
                            ----------  ----------  ----------  ----------
                                 6,229       6,239      24,665      26,442
Gain on Litigation               1,391           -       1,391
Operating Income                 1,967         314       3,354       4,626
                                  12.1%        2.0%        5.2%        6.4%
Other Income (Expense), Net        134         (49)        328         (49)
                            ----------  ----------  ----------  ----------
Income Before Taxes              2,101         265       3,682       4,577
Income Tax Provision               373           2         916       1,613
                            ----------  ----------  ----------  ----------
Net Income                  $    1,728  $      263  $    2,766  $    2,964
                            ----------  ----------  ----------  ----------
Net Income Per Share -
 Basic                      $     0.24  $     0.04  $     0.39  $     0.42
                            ----------  ----------  ----------  ----------
Net Income Per Share -
 Diluted                    $     0.23  $     0.04  $     0.38  $     0.40
                            ----------  ----------  ----------  ----------
Weighted Average Number of
 Common Shares  - Basic          7,153       7,010       7,135       6,988
Weighted Average Number of
 Common Shares  - Diluted        7,446       7,313       7,375       7,438
Dividends Declared Per
 Common Share               $     0.06  $     0.06  $     0.24  $     0.24
                         Selected Balance Sheet Data
                          In Thousands (Unaudited)
                                         As of                 As of
                                      January 31,           January 31,
                                         2010                  2009
                                  -------------------- --------------------
Cash & Marketable Securities      $             23,760 $            22,105*
Current Assets                    $             49,939 $             48,023
Total Assets                      $             64,676 $             62,155
Current Liabilities               $              8,158 $              7,904
Shareholders' Equity              $             53,819 $             51,471
*Includes LT investments

Safe Harbor Statement

This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include those mentioned in Astro-Med's FY2009 annual report and its quarterly filings with the Securities and Exchange Commission.

Albert W. Ondis, CEO
Joseph P. O'Connell, CFO
Astro-Med, Inc.
(401) 828-4000

SOURCE: Astro-Med, Inc.

View all news

IR Contact

AstroNova, Inc.
Investor Relations Department
600 East Greenwich Avenue
West Warwick, RI 02893
Scott Solomon
Senior Vice President Sharon Merrill
Phone: (617) 542-5300

Email Alerts

Email Address *

Enter the code shown above.

Interactive Analyst Center Disclaimer

The financial data and other material provided to users in the pages of the website is for information purposes only. Users should not rely on information on this website for any purpose other than for obtaining general knowledge of AstroNova. Material may be changed or updated without notice.

AstroNova, Inc.